Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DIA President Ling Su On Bridging Gaps In China On The Road To Innovation: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

DIA President Ling Su has a unique perspective on the Chinese market, having served in senior R&D positions with industry – most recently at Novartis China – and as a regulator, including stints in China’s Ministry of Health and as a visiting scientist with U.S. FDA. He recently sat down with PharmAsia News to discuss innovation and the evolution taking place in China.

You may also be interested in...



Meet China’s New Innovators: Hua Medicine Looks To Take Flight With U.S. Venture Backing (Part 1)

When multinational pharmaceutical companies began to establish R&D facilities in China a decade ago, they counted on Chinese returnees, or "sea turtles," to head the new centers and help them get the lay of the land. Now, MNCs may soon be partnering - or competing - with these same sea turtles who have switched gears to become China's newest entrepreneurs

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China: An Interview With PharmAsia News (Part 2 of 2)

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.

Topics

Related Companies

UsernamePublicRestriction

Register

SC081938

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel